These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Moreillon P Clin Microbiol Infect; 2008 Apr; 14 Suppl 3():32-41. PubMed ID: 18318877 [TBL] [Abstract][Full Text] [Related]
51. Ceftobiprole - a case study. Page MG Expert Opin Drug Discov; 2007 Jan; 2(1):115-29. PubMed ID: 23496040 [TBL] [Abstract][Full Text] [Related]
52. Ceftaroline fosamil: a cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Poon H; Chang MH; Fung HB Clin Ther; 2012 Apr; 34(4):743-65. PubMed ID: 22444785 [TBL] [Abstract][Full Text] [Related]
53. Safety and tolerability of ceftobiprole. Grau S Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):34-36. PubMed ID: 31364340 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. Falcone M; Viale P; Tiseo G; Pai M Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):331-340. PubMed ID: 29373935 [TBL] [Abstract][Full Text] [Related]
55. Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia. Kiem S; Schentag JJ Semin Respir Crit Care Med; 2006 Feb; 27(1):51-67. PubMed ID: 16508882 [TBL] [Abstract][Full Text] [Related]
56. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia. Bartlett JG; Barie PS; Niederman MS; Wunderink RG Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654 [No Abstract] [Full Text] [Related]
57. Ceftobiprole medocaril: a new generation beta-lactam. Del Pozo JL; Patel R Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259 [TBL] [Abstract][Full Text] [Related]
58. Ceftobiprole and pneumonia in adults admitted to the emergency department is it time to assess a new therapeutic algorithm? Crapis M; Venturini S; Della Siega P; Tonizzo M; Garlatti E; Rosa R; Basso B; Pontoni E J Chemother; 2021 May; 33(3):174-179. PubMed ID: 32996844 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients. Rubino CM; Polak M; Schröpf S; Münch HG; Smits A; Cossey V; Tomasik T; Kwinta P; Snariene R; Liubsys A; Gardovska D; Hornik CD; Bosheva M; Ruehle C; Litherland K; Hamed K Pediatr Infect Dis J; 2021 Nov; 40(11):997-1003. PubMed ID: 34533489 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants. Li WZ; Wu HL; Chen YC; Guo BN; Liu XF; Wang Y; Wu JF; Zhang J Ann Transl Med; 2021 Jun; 9(11):936. PubMed ID: 34350251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]